Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients

Conditions

• Acute Myocardial Infarction Type 1

Eligibility Criteria

Sex

ALL

Age

18 Years - 79 Years

Healthy Volunteers

Not accepted

Interventions

• Deferiprone Tablets — DRUG
  Deferiprone tablets are the active medication for the active arm of the study groups. Randomization will be done by investigational drug services pharmacist and intervention will be double-blinded to investigators and patients.
• Placebo — DRUG
  Deferiprone placebo is the non-medicated formulation for a control arm of the study groups.

Study Details

The objective of this randomized, controlled pilot study is to determine the efficacy of Deferiprone to reduce the amount of free iron inside the hemorrhagic zone of myocardial infarction among hemorrhagic myocardial infarction patients.

Key Dates

Start date

Nov 8, 2022

Status verified

Mar 2026

Primary completion

Mar 31, 2029

Completion

Aug 31, 2029

Study Design

Enrollment

89 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Active Comparator: Hemorrhagic Myocardial Infarction - Deferiprone
  Enrolled patients with CMR confirmed presence of intramyocardial hemorrhage
• Active Comparator: Non-hemorrhagic Myocardial Infarction - Deferiprone
  Enrolled patients with CMR confirmed absence of intramyocardial hemorrhage
• Placebo Comparator: Hemorrhagic Myocardial Infarction - Placebo
  Enrolled patients with CMR confirmed presence of intramyocardial hemorrhage
• Placebo Comparator: Non-hemorrhagic Myocardial Infarction - Placebo
  Enrolled patients with CMR confirmed absence of intramyocardial hemorrhage

Primary Outcome Measure

Treatment Efficacy [ Time Frame: 6 months ]

Central Contacts

• Clinical Research Coordinator
  (317) 274-0985
  [email protected]

Locations (1)

Find similar trials in Indianapolis, IN